Bone drug hope for breast cancer patients
Doctors were mostly hoping to prevent complications and relapses when they gave young women a medicine to keep their bones strong during breast cancers treatment. Seven years later, they found it did more than that: The bone drug improved survival, as much as much chemotherapy does. The study found a 37 percent lower risk of death among women who received the bone drug, Zometa. In absolute terms, it meant that 4 to 5 more women out of every 100 were alive seven years later. It’s especially impressive considering that the women took the drug, given as an infusion every six months, for only three years.

Zometa (zow-MAY-tuh) should now be offered to all patients like those in this study – younger women forced into early menopause by hormone-blocking cancer treatments, some specialists said. Bone drugs called bisphosphonates have long been sold for treating osteoporosis. Those are daily pills. Zometa, made by the Swiss company Novartis AG, is given intravenously to treat breast cancers that has spread to the bone. All had surgery followed by hormone blockers, and half also received Zometa. Now, with seven years of follow-up, researchers see that Zometa not only helped keep cancer from coming back, but also improved survival. There were 33 deaths among women given the bone drug and 49 among those not treated with it. That magnitude of benefit is comparable to many chemotherapy treatments. Researchers think because Zometa strengthens bones, it’s tougher for cancer to spread there and the drug may also have direct effects against circulating cancer cells or microscopic tumors.

Zometa’s side effects were mostly fever and bone and joint pain, and doctors saw no cases of jawbone decay, a serious problem long linked to bisphosphonates. Zometa costs more than $1,000 in the U.S. and about half as much in Europe, though the price may drop when its U.S. patent expires in 2013. Novartis helped pay for the study and Gnant consults for the company. The bone drug proved disappointing though in a large study last year in postmenopausal women, who account for three-fourths of all breast cancers. But there was a glimmer of hope in the oldest patients.

Recent Comments